bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-30-2761

Order Name:
SARS-CoV-2 (COVID-19) IgM/IgG antibody (CMIA)

 
Useful For:
Detection of IgG and IgM antibodies to 2019-nCoV in human blood.
 
Methodology:
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
AliasesName:
Covid
Covid antibody
Covid IgM
Covid IgG
Covid Ig
 
 
 
Test Code:
090-30-2761

Order Name:
SARS-CoV-2 (COVID-19) IgM/IgG antibody (CMIA)

 
Collection Specimen Or Container:
Plain Blood 6 mL (Red Top) 1 tube
 
Specimen Testing Type:
Serum, minimum volume 1 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis: 4+

 
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum (keep in original tube) Room Temperature 8 hours
Serum Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code:
090-30-2761

Order Name:
SARS-CoV-2 (COVID-19) IgM/IgG antibody (CMIA)

 
Method detail:
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
Schedule:
Tested Daily (24 Hours)
 
Turnaround Time:
Specimen collected to reported within 2:00 Hours (120 Mins)
 
Performing Location:
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
090-30-2761

Order Name:
SARS-CoV-2 (COVID-19) IgM/IgG antibody (CMIA)

 
 
Clinical Information:
IgG:
The SARS-CoV-2 IgG assay is designed to detect immunoglobulin class G (IgG) antibodies to the nucleocapsid protein of SARS-CoV-2 in serum and plasma from patients with signs and symptoms of infection who are suspected of coronavirus disease (COVID-19) or in serum and plasma of subjects that may have been infected by SARS-CoV-2.

IgM : 
The SARS-CoV-2 IgM assay is designed to detect immunoglobulin class M (IgM) antibodies to the spike protein of SARS-CoV-2 in serum and plasma from individuals who are suspected to have had coronavirus disease (COVID-19) or in subjects that may have been infected by SARS-CoV-2.
 
Reference Value:
Negative
 
Clinical Reference:
  1. 1.Manufacturer’s Reagent package insert, Architect SARS-CoV-2 IgG, June 2020, Abbott Ireland Diagnostics Division, Finisklin Business Park, Sligo, Ireland
  2. 2.Manufacturer’s Reagent package insert, Architect SARS-CoV-2 IgM, September 2020, Abbott Ireland Diagnostics Division, Finisklin Business Park, Sligo, Ireland